| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/2000 | Human,Mouse,Rat |
| Aliases | CRL2; TSLPR; CRLF2Y |
| WB Predicted band size | 42 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human CRLF2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于CRLF2抗体的3篇参考文献及其摘要概括：
---
1. **文献名称**：*CRLF2 overexpression in pediatric acute lymphoblastic leukemia*
**作者**：Harvey RC et al.
**摘要**：研究揭示了CRLF2在儿童急性淋巴细胞白血病(ALL)中的异常高表达，及其与JAK2基因突变的关联，提出CRLF2抗体可作为该亚型白血病的潜在诊断标志物。
2. **文献名称**：*Therapeutic targeting of CRLF2 in B-cell precursor ALL*
**作者**：Yoda A et al.
**摘要**：通过单克隆抗体和CAR-T细胞靶向CRLF2.研究证明其在抑制白血病细胞增殖中的作用，为CRLF2抗体在免疫治疗中的应用提供实验依据。
3. **文献名称**：*CRLF2 as a surface marker for minimal residual disease detection*
**作者**：Roberts KG et al.
**摘要**：探讨利用CRLF2特异性抗体通过流式细胞术监测ALL患者治疗后微小残留病灶(MRD)，验证其在预后评估中的临床价值。
---
以上文献均聚焦于CRLF2在白血病中的生物学功能及其抗体在诊断与治疗中的应用。
The cytokine receptor-like factor 2 (CRLF2) is a transmembrane protein belonging to the type I cytokine receptor family, structurally homologous to receptors like thrombopoietin receptor (TPOR) and erythropoietin receptor (EPOR). It forms heterodimeric complexes, notably with the interleukin-7 receptor alpha (IL7Rα), to serve as a receptor for thymic stromal lymphopoietin (TSLP), a cytokine critical in T-cell maturation and allergic inflammation. CRLF2 gained prominence due to its pathogenic role in hematologic malignancies, particularly B-cell acute lymphoblastic leukemia (B-ALL). Aberrant CRLF2 expression, often caused by chromosomal rearrangements (e.g., P2RY8-CRLF2 or IGH-CRLF2 fusions) or mutations, leads to constitutive activation of JAK-STAT signaling, promoting leukemogenesis. Overexpression is frequently observed in high-risk B-ALL subtypes, including Philadelphia chromosome-like (Ph-like) ALL and Down syndrome-associated ALL.
Antibodies targeting CRLF2 are essential tools for diagnosing CRLF2-driven malignancies, detecting overexpression via flow cytometry or immunohistochemistry. They also aid in research to elucidate CRLF2 signaling mechanisms and evaluate therapeutic strategies, such as JAK inhibitors or CRLF2-directed biologics. Despite progress, challenges remain in understanding CRLF2's context-dependent roles in normal immunity versus oncogenesis, driving ongoing studies to optimize targeted therapies and overcome resistance.
×
